help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on August 29, 2007, doi:10.1164/rccm.200705-664OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200705-664OCv1
176/10/957    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flume, P. A.
Right arrow Articles by Marshall, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flume, P. A.
Right arrow Articles by Marshall, B.
American Journal of Respiratory and Critical Care Medicine Vol 176. pp. 957-969, (2007)
© 2007 American Thoracic Society
doi: 10.1164/rccm.200705-664OC

Original Article

Cystic Fibrosis Pulmonary Guidelines

Chronic Medications for Maintenance of Lung Health

Patrick A. Flume1, Brian P. O'Sullivan2, Karen A. Robinson3, Christopher H. Goss4, Peter J. Mogayzel, Jr.5, Donna Beth Willey-Courand6, Janet Bujan7, Jonathan Finder8, Mary Lester9, Lynne Quittell10, Randall Rosenblatt11, Robert L. Vender12, Leslie Hazle13, Kathy Sabadosa14 and Bruce Marshall13

1 Departments of Medicine and Pediatrics, Medical University of South Carolina, Charleston, South Carolina; 2 Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts; 3 Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland; 4 Department of Medicine, University of Washington, Seattle, Washington; 5 Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, Maryland; 6 Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, Texas; 7 Department of Nursing, Texas Children's Hospital, Houston, Texas; 8 Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; 9 Department of Respiratory Therapy, Medical University of South Carolina, Charleston, South Carolina; 10 Department of Pediatrics, Columbia University, New York, New York; 11 Department of Medicine, University of Texas Southwestern, Dallas, Texas; 12 Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania; 13 Cystic Fibrosis Foundation, Bethesda, Maryland; and 14 Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Correspondence and requests for reprints should be addressed to Patrick A. Flume, M.D., Medical University of South Carolina, 96 Jonathan Lucas Street, 812-CSB, Charleston, SC 29425. E-mail: flumepa{at}musc.edu

Rationale: Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease have difficulty clearing pathogens from the lung and experience chronic pulmonary infections and inflammation. Death is usually a result of respiratory failure. Newly introduced therapies and aggressive management of the lung disease have resulted in great improvements in length and quality of life, with the result that the median expected survival age has reached 36 years. However, as the number of treatments expands, the medical regimen becomes increasingly burdensome in time, money, and health resources. Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety.

Objectives: The Cystic Fibrosis Foundation therefore established a committee to examine the clinical evidence for each therapy and to provide guidance for the prescription of these therapies.

Methods: The committee members developed and refined a series of questions related to drug therapies used in the maintenance of pulmonary function. We addressed the questions in one of three ways, based on available evidence: (1) commissioned systematic review, (2) modified systematic review, or (3) summary of existing Cochrane reviews.

Conclusions: It is hoped that the guidelines provided in this article will facilitate the appropriate application of these treatments to improve and extend the lives of all individuals with cystic fibrosis.

Key Words: antibiotics • antiinflammatory agents • bronchodilators • mucolytics • saline solution, hypertonic




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
P. A. Flume, P. J. Mogayzel Jr., K. A. Robinson, R. L. Rosenblatt, L. Quittell, B. C. Marshall, and the Clinical Practice Guidelines for Pulmonary The
Cystic Fibrosis Pulmonary Guidelines: Pulmonary Complications: Hemoptysis and Pneumothorax
Am. J. Respir. Crit. Care Med., August 1, 2010; 182(3): 298 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. E. Grinwis, C. D. Sibley, M. D. Parkins, C. S. Eshaghurshan, H. R. Rabin, and M. G. Surette
Macrolide and Clindamycin Resistance in Streptococcus milleri Group Isolates from the Airways of Cystic Fibrosis Patients
Antimicrob. Agents Chemother., July 1, 2010; 54(7): 2823 - 2829.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
P. Anderson
Emerging therapies in cystic fibrosis
Therapeutic Advances in Respiratory Disease, June 1, 2010; 4(3): 177 - 185.
[Abstract] [PDF]

Home page
 JAMAHome page
L. Saiman, M. Anstead, N. Mayer-Hamblett, L. C. Lands, M. Kloster, J. Hocevar-Trnka, C. H. Goss, L. M. Rose, J. L. Burns, B. C. Marshall, et al.
Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa: A Randomized Controlled Trial
JAMA, May 5, 2010; 303(17): 1707 - 1715.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. J. Mogayzel Jr. and P. A. Flume
Update in Cystic Fibrosis 2009
Am. J. Respir. Crit. Care Med., March 15, 2010; 181(6): 539 - 544.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
A. R. Smyth, A. Barbato, N. Beydon, H. Bisgaard, K. de Boeck, P. Brand, A. Bush, B. Fauroux, J. de Jongste, M. Korppi, et al.
Respiratory medicines for children: current evidence, unlicensed use and research priorities
Eur. Respir. J., February 1, 2010; 35(2): 247 - 265.
[Abstract] [Full Text] [PDF]

Home page
 ACCP/AAP Ped Pul Brd RevHome page
M. W. Konstan
Cystic Fibrosis and Lung Transplantation
ACCP AAP Ped Pul Brd Rev, January 1, 2010; 1(0): 257 - 264.
[Extract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. A. Flume, P. J. Mogayzel Jr., K. A. Robinson, C. H. Goss, R. L. Rosenblatt, R. J. Kuhn, B. C. Marshall, and and the Clinical Practice Guidelines for Pulmonary
Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations
Am. J. Respir. Crit. Care Med., November 1, 2009; 180(9): 802 - 808.
[Abstract] [Full Text] [PDF]

Home page
 Pediatr. Rev.Home page
G. S. Montgomery and M. Howenstine
Cystic Fibrosis
Pediatr. Rev., August 1, 2009; 30(8): 302 - 310.
[Full Text] [PDF]

Home page
 ChestHome page
A. L. Quittner, A. C. Modi, C. Wainwright, K. Otto, J. Kirihara, and A. B. Montgomery
Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway Infection
Chest, June 1, 2009; 135(6): 1610 - 1618.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. Z. Retsch-Bogart, A. L. Quittner, R. L. Gibson, C. M. Oermann, K. S. McCoy, A. B. Montgomery, and P. J. Cooper
Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis
Chest, May 1, 2009; 135(5): 1223 - 1232.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. Ratjen
Update in Cystic Fibrosis 2008
Am. J. Respir. Crit. Care Med., March 15, 2009; 179(6): 445 - 448.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. S. McCoy, A. L. Quittner, C. M. Oermann, R. L. Gibson, G. Z. Retsch-Bogart, and A. B. Montgomery
Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 921 - 928.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. J. Accurso
Update in Cystic Fibrosis 2007
Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1058 - 1061.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society